What drives disease in multiple sclerosis: Inflammation or neurodegeneration?

Clinical and Experimental Neuroimmunology

Volumn 1, Issue 1, 2010, Pages 2-11

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Diffuse brain injury; Focal white matter lesions; Inflammation; Multiple sclerosis; Neurodegeneration

Indexed keywords

ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEMYELINATION; DISEASE COURSE; ENCEPHALITIS; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PRIORITY JOURNAL; REVIEW; WHITE MATTER;

EID: 79952232716     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/j.1759-1961.2009.00003.x     Document Type: Review

References (60)

1. Charcot JM. Lecons sur les maladies du systeme nerveux faites a la Salpetriere. Thome 1, 4th edn. Paris: Bureau du Progress Medical, V.A. Delahaye et Co; 1880.
2. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA. 2004; 101(Suppl 2): 14599-606.
3. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol. 2009; 22: 226-32.
4. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology. 2009; 72: 1008-15.
5. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease. Ann Neurol. 2009; 65: 239-48.
6. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008; 31: 247-69.
7. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003; 60: 640-6.
8. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993; 34: 661-9.
9. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trial. Neurology. 2009; 72: 705-11.
10. Kornek B, Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 1999; 9: 651-6.
11. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997; 120: 393-9.
12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338: 278-85.
13. Kornek B, Storch M, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am J Pathol. 2000; 157: 267-76.
14. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain. 2000; 123: 1845-9.
15. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain. 2005; 128: 29-34.
16. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006; 129: 1507-16.
17. Kidd T, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999; 122: 17-26.
18. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50: 389-400.
19. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005; 128: 2705-12.
20. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003; 9: 323-31.
21. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004; 55: 458-68.
22. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-17.
23. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998; 43: 809-14.
24. Narayana PA, Doyle TJ, Lai D, Wolinski JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 1998; 43: 56-71.
25. Van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol. 2009; 22: 207-13.
26. Marik C, Felts P, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain. 2007; 130: 2800-15.
27. Gay FW, Drye GW, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of fplaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion. Brain. 1997; 120: 1461-83.
28. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Brück W, et al. Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropath Exp Neurol. 2003; 62: 25-33.
29. Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T-cells in multiple sclerosis. Nat Med. 2008; 14: 1227-35.
30. Ariyannur PS, Madhavarao CN, Namboodiri AM. N-acetylaspartate synthesis in the brain: mitochondria versus microsomes. Brain Res. 2008; 1227: 34-41.
31. Signoretti S, Marmarou A, Tavazzi B, Lazzarino G, Beaumont A, Vagnozzi R. N-acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J Neurotrauma. 2001; 18: 977-91.
32. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain. 2008; 131: 1722-35.
33. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Redland E, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation. J Neuroinflammation. 2009; 4: 30-50.
34. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ. Sulfatide, a major lipid component of myelin sheaths, activates inflammatory responses as an endofgeneous stimulator in brain resident immune cells. J Immunol. 2008; 181: 8077-87.
35. Kerschensteiner M, Gallmeier E, Behrens L, Klinkert WEF, Kolbeck R, Hoppe E, et al. Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999; 189: 865-70.
36. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatr. 1962; 25: 315-20.
37. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci. 2006; 245: 123-6.
38. Geurts JJ, Bo L, Roosendaal SD, Hazes T, Daniels R, Barkhof F, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropath Exp Neurol. 2007; 66: 819-27.
39. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007; 17: 38-44.
40. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130: 1089-104.
41. Storch MK, Bauer J, Linington C, Olsson T, Weissert R, Lassmann H. Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J Neuropathol Exp Neurol. 2006; 65(12):1137-42.
42. Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C. A new focal EAE model of cortical demyelination: MS-like lesions with rapid resolution of inflammation and extensive remyelination. Brain. 2006; 129: 1972-83.
43. Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bo L. The pathology of multiple sclerosis is location dependent: no significant complement activation is detected in purely cortical lesions. J Neuropath Exp Neurol. 2005; 64: 147-55.
44. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006; 59: 478-89.
45. Bergers E, Bot JC, De Groot CJ, Polman CH, Nijeholt GJ, Castelijns JA, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology. 2002; 59: 1766-71.
46. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis. Brain. 2009; 132: 1175-89.
47. Brück W, Porada P, Poser S, Riechmann P, Hanefeld F, Kretschmar H-A, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 1995; 38: 788-96.
48. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006; 65: 855-65.
49. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004; 14: 164-74.
50. Ragonsese P, Aridon P, Salemi G, D'Amelio M, Savettieri G. Mortality in multiple sclerosis: a review. Eur J Neurol. 2008; 15: 123-7.
51. Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H. Multiple sclerosis and Alzheimer's disease. Ann Neurol. 2008; 63: 174-83.
52. Noorbakhsh F, Overall CM, Power C. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci. 2009; 32: 88-100.
53. Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest. 2008; 118: 3557-63.
54. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol. 2009; 21: 172-88.
55. Trapp B, Stys P. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009; 8: 280-91.
56. Mahad D, Ziabreva I, Campbell G, Lax N, Hanson PS, Lassmann H, et al. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009; 132: 1161-74.
57. Evangelou N, Konz D, Esiri MM, Smith S, Palace Jand Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain. 2001; 124: 1813-20.
58. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005; 133: 3-13.
59. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci. 2000; 177: 95-103.
60. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000; 192: 393-404.